Table 1.
Baseline characteristics
| Male, n (%) | 67 (71) |
| Age (years), median (IQR) | 44 (38–48) |
| MSM, n (%) | 46 (48) |
| Ethnicity, n (%) | |
| white | 50 (53) |
| black | 38 (40) |
| other/unknown | 7 (7) |
| Nadir CD4 count (cells/mm3), median (IQR) | 180 (70–250) |
| CD4 count at PI monotherapy initiation (cells/mm3), median (IQR) | 455 (290–640) |
| Number of previous ART regimens prior to PI monotherapy, median (IQR) | 4 (2–7) |
| ART experienced before PI monotherapy, n (%) | 92 (97) |
| PI experienced before PI monotherapy, n (%) | 77 (81) |
| Detectable plasma HIV RNA >50 copies/mL at start of episode, n (%) | 40 (41) |
| Plasma HIV RNA at start of episode for the 40 episodes that started during viraemia (copies/mL), median (IQR) | 6500 (510–46 000) |
| Duration of viral suppression prior to PI monotherapy for the 57 episodes that started during viral suppression (weeks), median (IQR) | 352 (181–555) |
| Follow-up time (weeks), median (IQR) | 143 (118–186) |
Denominators of 95 patients and 97 episodes.